Abstract
e18819 Background: Cancer patients have a higher rate of thrombotic events (TEs) compared to the general population. Site, stage and treatment related factors, among others, contribute to this increased risk. Regarding treatment, various anticancer agents have been linked with increased risk of TEs. However, despite the incidence and impact of TEs, available data is inadequate, and most PRO-based analyses focus on individual agents. This analysis aims to utilise PROs to identify correlations between several anticancer agents and the incidence of TEs. Methods: CareAcross is an online interactive platform which collects Patient Reported Outcomes and provides support to cancer patients based on their condition and needs. Specific cancer treatments are among the collected data. Additionally, breast and lung cancer patients engaging with the platform were asked to report, among others, whether they have had a TE during their cancer journey. Data was aggregated and anonymised in order to evaluate the likelihood of TEs for each cancer treatment. Results: Based on data captured as of February 2023, 2011 breast (13% metastatic) and 573 lung (51% metastatic) cancer patients from 8 (mostly European) countries had provided real world data on cancer treatments and TEs. Among them, 144 (7.2%) breast cancer and 97 (16.9%) lung cancer patients reported TEs. Breast cancer treatments with higher than average association with TEs included aromatase inhibitors (8.1% of 569), tamoxifen (8.0% of 462), trastuzumab (9.0% of 221), CDK4/6 inhibitors (8.7% of 126). Among lung cancer treatments, cisplatin was associated with higher incidence than carboplatin (20.0% of 110 vs 13.4% of 112); others included pembrolizumab (21.8% of 78), pemetrexed (13.2% of 68), alectinib (29.4% of 34), osimertinib (12.1% of 33), afatinib (29% of 31). The Table provides a summary for this subset of anticancer agents. Conclusions: Based on the analysis of PROs from the CareAcross platform, it is confirmed that lung cancer patients have a higher risk of TEs compared to breast cancer patients. Moreover, certain anticancer agents appear to be linked with increased risk of TEs. In breast cancer, aromatase inhibitors and tamoxifen show similar association; in lung cancer, cisplatin appears to be a stronger factor compared to carboplatin. Finally, it is worth mentioning that some immunotherapies and targeted agents in lung cancer were found to have strong association with TEs. More PROs would improve the accuracy of these findings. [Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
